This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
MDT vs. ABT: Which Stock Is the Better Value Option?
by Zacks Equity Research
MDT vs. ABT: Which Stock Is the Better Value Option?
Should ISRG Stock Be Part of Your Portfolio Ahead of Q3 Earnings?
by Zacks Equity Research
Intuitive Surgical's third-quarter results are likely to reflect solid performance in the company's Instruments & Accessories segment. Improving margins buoy optimism.
Medtronic (MDT) Rises Yet Lags Behind Market: Some Facts Worth Knowing
by Zacks Equity Research
In the latest trading session, Medtronic (MDT) closed at $89.36, marking a +0.57% move from the previous day.
AtriCure Gets CE Mark for EnCompass Clamp, Expands in Europe
by Zacks Equity Research
ATRC's EnCompass Clamp receives a CE Mark, enabling European surgeons to access faster, simpler heart ablation in cardiac surgeries with advanced radiofrequency technology.
GE HealthCare Acquires Intelligent Ultrasound's Clinical AI Business
by Zacks Equity Research
GEHC acquires clinical AI business to aid its ultrasound portfolio with AI-driven image analysis tools.
SNN Boosts Knee Revision Surgery With Its LEGION Hinged Knee System
by Zacks Equity Research
Smith & Nephew introduces the LEGION Hinged Knee System with OXINIUM Technology, elevating knee revision surgery through innovation.
InspireMD Gains FDA Premarket Approval for CGuard Prime Carotid Stent
by Zacks Equity Research
NSPR gains premarket approval for its CGuard Prime carotid stent system for use in United States for treating carotid artery stenosis.
CRL to Aid Lundbeck's Neurological Drug Research With AI-Backed Logica
by Zacks Equity Research
Charles River and Lundbeck sign an agreement to use Logica to advance the discovery of novel neurological drugs.
MDT Stock Trades Near 52-Week High: Is it a Smart Buy Now?
by Urmimala Biswas
The latest rate cut should help Medtronic expand in the AFib, structural heart, robotics, neuromodulation, hypertension and diabetes markets.
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks
by Zacks Equity Research
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Intuitive Surgical Stock Declines 0.7% in a Month: Is It Losing Steam?
by Zacks Equity Research
ISRG stock has maintained an uptrend so far this year on the back of robust da Vinci portfolio performance. However, the stock has declined in the past month. Let's see if the trend might change.
The Zacks Analyst Blog JPMorgan, Medtronic, Shopify and Perma-Pipe International
by Zacks Equity Research
JPMorgan, Medtronic, Shopify and Perma-Pipe International are included in this Analyst Blog.
Top Research Reports for JPMorgan Chase, Medtronic & Shopify
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Medtronic plc (MDT) and Shopify Inc. (SHOP), as well as a micro-cap stock Perma-Pipe International Holdings, Inc. (PPIH).
Medtronic (MDT) Advances But Underperforms Market: Key Facts
by Zacks Equity Research
Medtronic (MDT) concluded the recent trading session at $88.26, signifying a +0.56% move from its prior day's close.
Reasons to Retain Medtronic Stock in Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about Medtronic due to strength in its Neurosurgery portfolio. Yet, mounting expenses pose a threat to the company's margins.
Positive Trial Outcome for PulseSelect PFA Likely to Boost MDT Stock
by Zacks Equity Research
Medtronic presents new clinical data on the PulseSelect PFA System and marks its launch in Japan.
Phibro (PAHC) Up 2.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Medtronic (MDT) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Medtronic (MDT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Medtronic (MDT) reachead $89.45 at the closing of the latest trading day, reflecting a +0.07% change compared to its last close.
MDT Stock Might Gain From Expanded AiBLE Ecosystem and New Partnership
by Zacks Equity Research
Medtronic expands AiBLE spine surgery ecosystem with new technologies and a partnership with Siemens Healthineers.
Axonics Stock Rises on Favorable Verdict in Patent Case With Medtronic
by Zacks Equity Research
AXNX stock continues to gain following a favorable court ruling last week in a patent litigation with Medtronic.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Bioventus Surges 103% in Six Months: Is the Stock Worth a Buy?
by Sundeep Ganoria
BVS' stock generates phenomenal returns, driven by double-digit revenue growth across the Pain Treatments and Surgical Solutions franchises.
Medtronic (MDT) Up 0.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Medtronic (MDT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ISRG Stock Rallies 14% in 3 Months: Is It Still Worth Buying?
by Indrajit Bandyopadhyay
Intuitive Surgical is making strides in the robotic-assisted surgery market with its existing and new launches. However, macro challenges are likely to continue to hurt its performance.